Clinical Trials Logo

Filter by:
NCT ID: NCT04051606 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Start date: July 31, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of Regorafenib in patients with recurrent or progressive glioblastoma (GBM) who have progressed on bevacizumab. Regorafenib is FDA approved administered as monotherapy during the study. 22 total patients are expected to participate in this study. Even though a participant may meet all the criteria for participation, it is possible that they will not be enrolled in this study.

NCT ID: NCT04051502 Active, not recruiting - Ovarian Cancer Clinical Trials

ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study

Start date: August 5, 2019
Phase:
Study type: Observational

The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.

NCT ID: NCT04051346 Active, not recruiting - Kidney Stone Clinical Trials

Dietary Oxalate and Innate Immunity in Kidney Stone Disease

Start date: March 5, 2021
Phase: N/A
Study type: Interventional

This study will test whether oxalate stimulates urinary crystals and impacts the immune system in healthy subjects using two controlled diets (low and high oxalate).

NCT ID: NCT04050709 Active, not recruiting - Solid Tumor Clinical Trials

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Start date: July 18, 2019
Phase: Phase 1
Study type: Interventional

Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with locally advanced or metastatic solid cancers.

NCT ID: NCT04050683 Active, not recruiting - Refractory Ascites Clinical Trials

Evaluation of Hemodynamic Parameters Following Transjugular Intrahepatic Portosystemic Shunt (TIPS)

Start date: September 25, 2019
Phase: N/A
Study type: Interventional

During a TIPS procedure, a shunt or stent (mesh tube) is passed down the jugular vein (the vein above the collarbone in the neck) using fluoroscopy (real time x-rays) guidance. Then, a stent is inserted between the portal vein (vein that carries blood from the intestines into the liver) to a hepatic vein (vein that carries blood away from the liver back to the heart). This means that blood that would usually gets filtered through the liver is now bypassing the liver and going directly to the heart. Because more blood will be flowing to the heart, the heart needs to be strong enough to handle the extra volume. This study is being done to determine the impact of the TIPS procedure on cardiac (heart) function by collecting data (heart pressures) during the TIPS procedure. Immediately after TIPS and at standard follow-up time points, labs and transthoracic echocardiograms (TTE or echo) will also be collected. The device(s) used in this study are neither the intervention studied nor the experimental variable of interest. Devices are commercially available and used, and procedures are performed, in accordance with the institution's standard of care.

NCT ID: NCT04050462 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Nivolumab Combined With BMS-986253 in HCC Patients

Start date: September 12, 2019
Phase: Phase 2
Study type: Interventional

A phase II clinical trial is utilized to examine whether BMS-986253 (25 subjects) or Cabiralizumab (25 subjects) when combined with Nivolumab offers improved radiographic objective response rates (ORR) over Nivolumab monotherapy (25 subjects) in advanced HCC patients.

NCT ID: NCT04050436 Active, not recruiting - Clinical trials for Cutaneous Squamous Cell Carcinoma

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

CERPASS
Start date: October 8, 2019
Phase: Phase 2
Study type: Interventional

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.

NCT ID: NCT04050176 Active, not recruiting - Clinical trials for Hypnotic Dependence Among Those With Insomnia

Use of Blinded Tapering for Hypnotic Discontinuation

Start date: December 16, 2019
Phase: Phase 2
Study type: Interventional

The study will employ a randomized longitudinal clinical trial design to evaluate the relative efficacy of a blinded hypnotic tapering protocol when used in combination with therapist delivered Cognitive Behavioral Therapy for Insomnia (CBTI) for enhancing hypnotic discontinuation rates. A blinded SMT+CBTI intervention will be compared to open-label SMT+CBTI.

NCT ID: NCT04049760 Active, not recruiting - Fabry Disease Clinical Trials

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

Start date: October 14, 2019
Phase: Phase 3
Study type: Interventional

This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants

NCT ID: NCT04049695 Active, not recruiting - Clinical trials for Cognitive Dysfunction

Improving Cognition After Cancer

ICAN
Start date: September 9, 2019
Phase: N/A
Study type: Interventional

This study will test whether a physical activity intervention can improve cognition in breast cancer survivors and help the development of physical activity guidelines for cognition in breast cancer survivors.